Status:
COMPLETED
Role of Vitamin E in Gaucher Disease Patients
Lead Sponsor:
Ain Shams University
Conditions:
Gaucher Disease
Eligibility:
All Genders
2-18 years
Phase:
PHASE3
Brief Summary
gaucher disease (GD) can be classified into three clinical types .type 1,the most common type ,is the chronic non neuronpathic form of the disease,which shows gighly variable signs and symptoms and va...
Detailed Description
enzymatic defeciency in gaucher disease patients may induce a cascade of events that result in side effects, such as the production of reactive oxygen species(ROS) and reactive nitrogen species(RNS) t...
Eligibility Criteria
Inclusion
- children and adolescents aged fron 2 to 18 years old with gaucher disease both type 1 and type 3 diagnosed clinically and confirmed by laboratory analysis patients who are on stable enzyme replacement therapy for at least 6 months -
Exclusion
- patients with infection or another inflammatory condition patients on multivitamin therapy known chronic liver disease (viral hepatitis,HIV) patients with renal impairement defined as creatinine level greater 1.2 for female and greater than 1.4 for male.
- \-
Key Trial Info
Start Date :
March 3 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 5 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06211478
Start Date
March 3 2023
End Date
October 5 2023
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University
Cairo, Abbasia, Egypt, 11517